Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,810 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Type 1 Clear all
Recruiting Early Phase 1 Interventional

The Effects of Fluoxetine and/or DHEA

NCT03228732
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo Oral Tablet, Fluoxetine, DHEA, Fluoxetine and DHEA
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

NCT01023581
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 21, 2026, 11:15 PM EDT
Approved For Marketing No phase listed Expanded access

Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT03791567
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Donislecel (allogeneic islets of Langerhans for transplant)
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control

NCT02556398
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sugar Sleuth
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
25 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 21, 2026, 11:15 PM EDT
Suspended Not applicable Interventional

A Study to Improve Diabetes Management Among Adults Experiencing Severe Hypoglycemia

NCT04874532
View directory record Official record
Conditions
Diabetes, Hypoglycemia, Diabetes Type 1, Diabetes Type 2
Interventions
Community Paramedic Program, Education Material
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337
View directory record Official record
Conditions
IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 21, 2026, 11:15 PM EDT
Active, not recruiting Phase 1 Interventional

An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

NCT04590872
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Tolerogenic Dendritic Cell Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multicenter Assessment of the Pancreas in Type 1 Diabetes

NCT03585153
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Non-contrast magnetic resonance imaging
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2050
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes

NCT04506151
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sleep-Opt, Healthy Living
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Pilot of Pragmatic Delivery of Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes

NCT06405386
View directory record Official record
Conditions
Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus, Distress, Emotional
Interventions
ReCharge, TakeCharge
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 21, 2026, 11:15 PM EDT
Active, not recruiting Phase 2 Interventional

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

NCT06812988
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed No phase listed Observational

Use of CoG by Patients With Diabetes Mellitus

NCT03840161
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
non-invasive tissue glucose prediction
Device
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 11:15 PM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379
View directory record Official record
Conditions
Solid Tumor, Unresectable or Metastatic Melanoma
Interventions
CX-072, Ipilimumab
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas

NCT02105324
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 11 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

NCT00694122
View directory record Official record
Conditions
Type 1 Diabetes, Dawn Phenomenon
Interventions
Lantus (glargine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Behavioral Family Therapy and Type One Diabetes

NCT03720912
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Online Learning Modules
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
2 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 1 Interventional

Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study

NCT02877771
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Insulin Pump
Interventions
t:slim insulin pump with predictive low glucose suspend
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 21, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Implementation Trial of Implementation Toolkits for Diabetes Coaching

NCT07766811
View directory record Official record
Conditions
Implementation Science, Type 1 Diabetes in Adolescence, Implementation Strategies
Interventions
Base Implementation Toolkit (BIT), BIT-Enhanced, BIT-Sustainment
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

NCT02414958
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 2 Interventional

Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients

NCT02861157
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Planet T1D
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03738865
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Novo Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Walnut Creek, California • Atlanta, Georgia • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 21, 2026, 11:15 PM EDT
Completed No phase listed Observational

Accuracy Characterization Study

NCT01932944
View directory record Official record
Conditions
Type2 Diabetes, Type1diabetes, Insulin Dependent Diabetes
Interventions
No treatment
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Walnut Creek, California • Rainier, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 21, 2026, 11:15 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Genetics of Diabetes in Southern California Chinese Americans

NCT00824395
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 21, 2026, 11:15 PM EDT